An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for estrogen-responsive breast cancer, providing practical guidance for both osteoporosis specialists and oncologists. Aromatase inhibitors are a cornerstone of adjuvant treatment for hormone-responsive breast cancer, significantly reducing the risk of recurrence. However, they also accelerate bone resorption, leading to a higher incidence of osteoporosis and fractures. Updating recommendations from 2017, the statement is by experts from the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. It incorporates information from recent clinical trials, systematic reviews, and meta-analyses. Also, it provides a treatment algorithm to assess fracture risk and guide bone-directed therapy in women receiving aromatase inhibitors.

The antibody also has potential to treat a broad array of other conditions, including autoimmune disorders, cancer and diabetes, research indicates.

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by researchers led by Radboud university medical center in a study published in The Lancet Digital Health. The use of AI could reduce workload and save millions of euros annually.

Ali Weinstein, professor of global and community health and senior scholar at the Center for the Advancement of Well-Being studied how breast cancer survivors respond to physically and mentally tiring tasks. Researchers measured changes in both inflammation and participants’ self-reported fatigue, two common symptoms among breast cancer survivors that are believed to be connected, impact quality of life, and may also play a role in cancer recurrence.